Core Viewpoint - Junshi Biosciences (01877) announced that its controlling shareholder and chairman, Mr. Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months starting from April 12, 2025, with a minimum of RMB 50 million allocated for A-shares [1] Group 1 - Mr. Xiong Jun intends to acquire shares through the Shanghai Stock Exchange and Hong Kong Stock Exchange, utilizing methods such as centralized bidding and block trading [1] - As of October 11, 2025, the share acquisition plan is more than halfway through, but Mr. Xiong has not yet made any purchases due to factors such as reporting periods, equity incentive matters, and funding arrangements [1] - The acquisition plan remains unfulfilled, and Mr. Xiong will continue to seek opportunities to increase his stake during the implementation period [1]

Core Viewpoint - The chairman of Junshi Biosciences, Mr. Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months, starting from April 12, 2025, with a minimum of RMB 50 million allocated for A-shares [1] Group 1 - Mr. Xiong Jun has not yet executed the share purchase plan due to various factors including reporting periods, equity incentive matters, and funding arrangements [1] - The share purchase plan is still ongoing, and Mr. Xiong intends to proceed with the acquisition of shares during the implementation period [1] - The plan may face risks due to changes in capital market conditions or other unpredictable factors that could hinder the expected outcomes of the share purchase [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司關於控股股東、實際控制人之一兼董事長增持股 份進展暨增持時間過半公告》，僅供參閱。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年10月10日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 本公司董事会、全体董事及相关股东保证本公告 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-061 上海君实生物医药科技股份有限公司 关于控股股东、实际控制人之一兼董事长 增持股份进展暨增持时间过半公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： | 增持主体名称 | 熊俊 | | | | --- | --- | --- | --- | | 增持主体身份 | 控股股东、实控人 | 是 | 否 | | | 控股股东、实控人的一致行动人 | 是 | 否 | | | 直接持股 5%以上股东 | 是 | 否 | | | 董事、监事和高级管理人员 | 是 | 否 | | | 其他：__________ | | | 一、增持主体的基本情况 | 增持前持股比例 | | | --- | --- | | 增持前持股数量 （占总股本） | 87,856,618 股 8.56% | 注 1：熊俊先生直接持有公司股份 87,856,618 股（包含 87,854,018 股 A 股和 2,600 股 H 股，其中由 HK ...

Market Performance - The Hong Kong stock market continued its decline, with notable drops in several biotech companies [1] - Innovent Biologics (09969) fell by 11.19%, closing at 14.760, with a market capitalization of 26.021 billion and a year-to-date increase of 141.18% [2] - Rongchang Biologics (09995) decreased by 10.22%, with a latest price of 95.350 and a total market value of 53.74 billion, reflecting a year-to-date increase of 562.15% [2] - WuXi AppTec (02268) and WuXi Biologics (02269) experienced declines of 5.68% and 5.32%, respectively, with market caps of 89.818 billion and 1585.28 billion [2] - Other companies such as Fuhong Hanlin (02696) and Kelun-Biotech (06990) also saw declines of over 4% [1][2] Company Highlights - Innovent Biologics has shown a significant year-to-date performance increase of 141.18% despite the recent drop [2] - Rongchang Biologics has the highest year-to-date increase among the listed companies at 562.15% [2] - WuXi Biologics and WuXi AppTec have maintained strong year-to-date increases of 120.84% and 138.50%, respectively [2] - Fuhong Hanlin and Kelun-Biotech also reported substantial year-to-date increases of 205.49% and 199.33% [2]

Core Viewpoint - The Hong Kong biopharmaceutical stocks continued to decline, with significant drops in several key companies, indicating a bearish trend in the sector [1]. Group 1: Stock Performance - Innovent Biologics (09969) experienced a decline of 11.19%, with a latest price of 14.760 and a total market capitalization of 26.021 billion, despite a year-to-date increase of 141.18% [2]. - Rongchang Biologics (09995) fell by 10.22%, with a latest price of 95.350 and a market cap of 53.747 billion, showing a remarkable year-to-date increase of 562.15% [2]. - WuXi AppTec (02268) saw a decrease of 5.68%, with a latest price of 73.100 and a market cap of 89.818 billion, maintaining a year-to-date increase of 138.50% [2]. - WuXi Biologics (02269) dropped by 5.32%, with a latest price of 38.780 and a market cap of 158.528 billion, reflecting a year-to-date increase of 120.84% [2]. - Fuhong Hanlin (02696) declined by 4.42%, with a latest price of 72.400 and a market cap of 39.349 billion, showing a year-to-date increase of 205.49% [2]. - Kelun-Biotech (06990) decreased by 4.25%, with a latest price of 488.800 and a market cap of 113.981 billion, with a year-to-date increase of 199.33% [2]. - WuXi AppTec (02359) fell by 4.19%, with a latest price of 114.400 and a market cap of 339.275 billion, reflecting a year-to-date increase of 109.21% [2]. - Gendicine (09688) saw a decrease of 2.83%, with a latest price of 25.440 and a market cap of 28.432 billion, with a year-to-date increase of 21.72% [2]. - CanSino Biologics (09926) declined by 2.05%, with a latest price of 128.800 and a market cap of 118.643 billion, reflecting a year-to-date increase of 112.19% [2]. - Junshi Biosciences (01877) fell by 2.02%, with a latest price of 29.100 and a market cap of 29.877 billion, showing a year-to-date increase of 151.30% [2].

Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Junshi Biosciences, indicating a significant level of financing and margin trading activity, suggesting investor interest and potential volatility in the stock [1][2][3] Group 2 - As of October 9, Junshi Biosciences experienced a trading decline of 0.96% with a transaction volume of 488 million yuan, and a net financing purchase of 11.61 million yuan [1] - The total financing and margin trading balance for Junshi Biosciences reached 1.4 billion yuan, with the financing balance accounting for 4.43% of the circulating market value, indicating a high level of leverage compared to the past year [1] - The company reported a revenue of 1.168 billion yuan for the first half of 2025, reflecting a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, showing a 36.01% increase in losses compared to the previous period [2]

Core Viewpoint - Junshi Bioscience reported a significant revenue increase and reduced net loss in H1 2025, driven by the performance of its flagship drug, Toripalimab, which is gaining traction in the domestic market with new indications approved [1] Financial Performance - In H1 2025, Junshi Bioscience's revenue reached 1.168 billion yuan, marking a year-on-year growth of 48.64% [1] - The net loss for the same period was 413 million yuan, reflecting a year-on-year reduction in loss by 36.01% [1] Product Development and Approvals - Toripalimab's domestic sales revenue was approximately 954 million yuan in H1 2025, representing a year-on-year increase of about 42% [1] - The drug has received approval for a total of 12 indications in China, with two new indications added in 2025, including liver cancer and melanoma [1] - A supplemental new drug application (sNDA) for the combination treatment of HER2+ urothelial carcinoma has been accepted by NMPA [1] Clinical Trials and Research - The PD-1/VEGF dual antibody JS207 is currently in Phase II clinical trials, showing strong anti-tumor activity in preclinical studies [1] - The drug is being explored in combination therapies across various cancer types, including NSCLC, CRC, TNBC, and liver cancer [1] - The international clinical trial for BTLA in LS-SCLC has enrolled nearly 400 participants [1] International Expansion - Junshi Bioscience has established commercial partnerships in over 80 countries, including the EU and the UK, with approvals in 40 regions such as the US, EU, UK, and Australia [1] - The company achieved commercialization in the US and received approval for nasopharyngeal cancer treatment in Australia in January 2025 [1] Investment Rating - The company maintains a "Buy" rating based on its robust pipeline and market performance [1]

Core Viewpoint - The domestic innovative drug industry is transitioning from a follower to FIC/BIC innovation, supported by engineer dividends, abundant clinical resources, and favorable policies, indicating a qualitative improvement as it enters the 2.0 era [1][2] Group 1: Industry Development - The innovative drug sector is expected to benefit from policy reforms in payment systems, enhancing the profitability of innovative drug companies as they commercialize domestic products [2] - The upcoming ESMO conference in mid-October is anticipated to provide new investment opportunities through the release of relevant clinical data and business development (BD) activities [2] Group 2: Investment Climate - The investment landscape has improved since early this year, with a notable reversal in the financing trend for the innovative drug industry, particularly in the A/H market [3] - The recovery of IPO projects and financing activities in the secondary market is expected to positively impact investment data in Q3, benefiting domestic CROs and upstream research sectors [3] Group 3: Policy Support - Continuous advancement of commercial medical insurance policies since 2025 is likely to accelerate payment system reforms, easing supply-demand conflicts and supporting domestic innovation [4] - Fiscal policy enhancements are expected to increase market interest in domestic medical equipment stocks [4] Group 4: Target Companies - A-share targets include: BeiGene (688235.SH), Hengrui Medicine (600276.SH), Kelun Pharmaceutical (002422.SZ), WuXi AppTec (603259.SH), Tigermed (300347.SZ), New Industry (300832.SZ), BGI Genomics (688114.SH), Huatai Medical (688617.SH), and Dian Diagnostics (300244.SZ) [5] - H-share targets include: Kelun Biotech (06990), CSPC Pharmaceutical (01093), China Biologic Products (01177), CanSino Biologics (09926), WuXi Biologics (02269), Junshi Biosciences (01877), and Zai Lab (09688) [5]

Core Viewpoint - The Hong Kong biopharmaceutical sector experienced a significant decline, with major companies reporting substantial drops in stock prices, indicating a bearish trend in the market [1]. Group 1: Stock Performance - Innovent Biologics (099660) saw a decline of 11.54%, with a latest price of 16.640 and a market capitalization of 293.36 billion, despite a year-to-date increase of 171.90% [2]. - Rongchang Biologics (09995) dropped by 9.20%, priced at 108.600, with a total market value of 612.08 billion, and a remarkable year-to-date increase of 654.17% [2]. - Kelun-Biotech (06990) fell by 7.71%, with a latest price of 533.000 and a market cap of 1,242.88 billion, while still showing a year-to-date increase of 226.39% [2]. - Tigermed (03347) decreased by 6.86%, priced at 43.960, with a market capitalization of 378.51 billion and a year-to-date increase of 44.25% [2]. - WuXi AppTec (02268) experienced a decline of 6.22%, with a latest price of 77.650 and a market cap of 954.09 billion, maintaining a year-to-date increase of 153.34% [2]. - CanSino Biologics (09926) dropped by 5.15%, priced at 134.500, with a market capitalization of 1,238.94 billion, and a year-to-date increase of 121.58% [2]. - Other companies like Junshi Biosciences (01877) and BeiGene (06160) also reported declines, with respective decreases of 3.16% and 2.48% [2].